» Articles » PMID: 29263894

Treatment of CD20-directed Chimeric Antigen Receptor-modified T Cells in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma: an Early Phase IIa Trial Report

Overview
Date 2017 Dec 22
PMID 29263894
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with relapsed or refractory non-Hodgkin lymphoma have a dismal prognosis. Chimeric Antigen Receptor (CAR)-modified T cells (CART cells) that targeted CD20 were effective in a phase I clinical trial for patients with advanced B-cell lymphomas. We performed a phase IIa trial to further assess the safety and efficacy of administering autologous anti-CD20 CART (CART-20) cells to patients with refractory or relapsed CD20 B-cell lymphoma. Eleven patients were enrolled, and seven patients underwent cytoreductive chemotherapy to debulk the tumors and deplete the lymphocytes before receiving T-cell infusions. The overall objective response rate was 9 of 11 (81.8%), with 6 complete remissions (CRs) and 3 partial remissions; no severe toxicity was observed. The median progression-free survival lasted for >6 months, and 1 patient had a 27-month continuous CR. A significant inverse correlation between the levels of the gene and disease recurrence or progression was observed. Clinically, the lesions in special sites, specifically the spleen and testicle, were refractory to CART-20 treatment. Collectively, these results together with our data from phase I strongly demonstrated the feasibility and efficacy of CART-20 treatment in lymphomas and suggest large-scale patient recruitment in a future study. This study was registered at www.clinicaltrials.org as NCT01735604.

Citing Articles

Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

de Oliveira Canedo G, Roddie C, Amrolia P Blood Adv. 2024; 9(4):704-721.

PMID: 39631066 PMC: 11869864. DOI: 10.1182/bloodadvances.2024013586.


A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?.

Andrea A, Chiron A, Sarrabayrouse G, Bessoles S, Hacein-Bey-Abina S Front Immunol. 2024; 15:1459818.

PMID: 39430751 PMC: 11486669. DOI: 10.3389/fimmu.2024.1459818.


Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies.

Zhou S, Yang Y, Jing Y, Zhu X Front Immunol. 2024; 15:1435635.

PMID: 39372412 PMC: 11449748. DOI: 10.3389/fimmu.2024.1435635.


The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.

Anurogo D, Luthfiana D, Anripa N, Fauziah A, Soleha M, Rahmah L Adv Pharm Bull. 2024; 14(2):314-330.

PMID: 39206402 PMC: 11347730. DOI: 10.34172/apb.2024.034.


Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure.

Xue F, Zheng P, Yang F, Liu R, Feng S, Guo Y Front Oncol. 2024; 14:1376490.

PMID: 38983927 PMC: 11232503. DOI: 10.3389/fonc.2024.1376490.


References
1.
Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244. DOI: 10.1200/JCO.1999.17.4.1244. View

2.
Kochenderfer J, Wilson W, Janik J, Dudley M, Stetler-Stevenson M, Feldman S . Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116(20):4099-102. PMC: 2993617. DOI: 10.1182/blood-2010-04-281931. View

3.
Sauter C, Matasar M, Meikle J, Schoder H, Ulaner G, Migliacci J . Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015; 125(16):2579-81. PMC: 4624450. DOI: 10.1182/blood-2014-10-606939. View

4.
Tabata R, Iwama H, Tabata C, Yasumizu R, Kojima M . CD5- and CD23-positive splenic diffuse large B-cell lymphoma with very low CD20 expression. J Clin Exp Hematop. 2014; 54(2):155-61. DOI: 10.3960/jslrt.54.155. View

5.
Swann J, Smyth M . Immune surveillance of tumors. J Clin Invest. 2007; 117(5):1137-46. PMC: 1857231. DOI: 10.1172/JCI31405. View